IP Library › Patent Application 11152376
Patent Application
App. No. 11/152,376

Method for prophylaxis and treatment of diabetic complications with 4{alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl}-3,5-dimethylbenzoic acid and derivatives

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/152,376
Abstract

The present invention relates to an agent for the prophylaxis and treatment of diabetic complications comprising, as an active ingredient, 4-[α-hydroxy-2-methyl-5(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for the prophylaxis and treatment of diabetic complications comprising administering an effective amount of this compound. The medicament of the present invention is useful for the prophylaxis and treatment of diabetic complications, namely, diabetic neuropathy, nephropathy, ophthalmopathy, arteriosclerosis and the like. The action of the drug is long-lasting for very small doses and a single administration a day is sufficient.

Claims (24)

1 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof.

2 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of sodium 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate.

3 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof.

4 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of sodium (S)-(−)- 4 -[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate 2/3 hydrate.

5 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof.

6 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of sodium 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate.

7 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof.

8 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of sodium (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate 2/3 hydrate.

9 . The method of claim 1 , wherein the diabetic ophthalmopathy is cataract.

10 . The method of claim 1 , wherein the diabetic ophthalmopathy is glaucoma.

11 . The method of claim 1 , wherein the diabetic ophthalmopathy is retinopathy.

12 . The method of claim 1 , wherein the diabetic ophthalmopathy is iritis.

13 . The method of claim 2 , wherein the diabetic ophthalmopathy is cataract.

14 . The method of claim 2 , wherein the diabetic ophthalmopathy is glaucoma.

15 . The method of claim 2 , wherein the diabetic ophthalmopathy is retinopathy.

16 . The method of claim 2 , wherein the diabetic ophthalmopathy is iritis.

17 . The method of claim 3 , wherein the diabetic ophthalmopathy is cataract.

18 . The method of claim 3 , wherein the diabetic ophthalmopathy is glaucoma.

19 . The method of claim 3 , wherein the diabetic ophthalmopathy is retinopathy.

20 . The method of claim 3 , wherein the diabetic ophthalmopathy is iritis.

21 . The method of claim 4 , wherein the diabetic ophthalmopathy is cataract.

22 . The method of claim 4 , wherein the diabetic ophthalmopathy is glaucoma.

23 . The method of claim 4 , wherein the diabetic ophthalmopathy is retinopathy.

24 . The method of claim 4 , wherein the diabetic ophthalmopathy is iritis.